Defense Health Agency

The Defense Health Agency (DHA), a major Defense Department subordinate agency that operates the military health system through military treatment facilities and research institutions, awarded 47,646 federal contracts cumulatively since 1995, with $479.13 billion in combined award potential value and $336.22 billion obligated. The agency transacts heavily across military medical centers, blood banks, research institutes, and health-IT platforms worldwide. DHA also administers $13.48 billion in cumulative federal grant funding to academic medical centers and research organizations, making it both a significant prime-contractor buyer and a substantial research funder.

DHA's contract activity shows recent deceleration: 4,878 awards in 2023, 4,501 in 2024, 4,209 in 2025, 2,025 in 2026, and 1 award recorded as of May 2027. Among the 7,483 distinct prime contractors awarded over the portfolio lifetime, competitive concentration is fragmented—the top five primes by award count hold only 7 percent of recent awards. Laboratory Corporation of America leads by count with 544 recent awards (though combined value of $254.9 million is modest), followed by Roche Diagnostics Corporation (261 awards) and New TECH Solutions, Inc. (235 awards). By potential value over the last five years, Medical Technology Enterprise Consortium dominates with $449.6 million across 63 awards, and Enterprise Resource Planning International, LLC holds $424.2 million across 86 awards, though many primes transact through Schedule task orders and BPA calls where dollar reporting is sparse. General Dynamics Information Technology, Inc. ranks in both top-by-count and top-by-value lists with 186 awards and $343.7 million potential value.

The contract set-aside mix is heavily unrestricted: 82 percent of awards carry no set-aside designation, while 12 percent are small-business set-asides (8(a) sole source, competitive 8(a), and total small business). Service-Disabled Veteran-Owned Small Business, Woman-Owned Small Business, HUBZone, and EDWOSB set-asides account for roughly 1 percent combined.

DHA's grant portfolio is more concentrated among elite research institutions. Over 7,580 cumulative grant awards since 2010, annual cadence declined from 973 awards in 2022 to 414 year-to-date in 2026. Grant recipients show concentrated funding: the top five recipients by award count hold 11 percent of recent awards, while the top five by federal dollars hold 6 percent. The Johns Hopkins University, University of Texas M.D. Anderson Cancer Center, The Regents of the University of California San Francisco, and The Henry M. Jackson Foundation for the Advancement of Military Medicine dominate the recipient base. Grants are predominantly Project Grants (94 percent of awards) with a smaller Cooperative Agreement share (6 percent). Federal dollars obligated total $13.48 billion cumulatively.

Representative recent contract opportunities span military medical logistics and specialized equipment: Biomedical Research Application Evaluation and Support (BRAES) solicitation HT942727RE006 (due December 2, 2026) seeks a Multiple Award IDIQ to support the Congressionally Directed Medical Research Programs; Nutrition Care Services solicitation HT940827RE003 (due November 4, 2026) seeks firm-fixed-price services across five military treatment facilities; and numerous sole-source and small-business set-aside opportunities for medical device maintenance, blood products, sterilization services, and clinical equipment dominate recent postings. Recent grant opportunities are not represented in the source data.